An Overview of Quality by Design (Qbd) in Pharmaceuticals

Ms. Dhopre Aishwarya N.[1], Mr.Pathan Ayaj S.[2], Ms Swami Vaishnavi B.[3], Ms Mokashe Vaishnavi N.[4], Mr. Pathan Aslam H.[5], Mr. Gaikwad Rushikesh S.[6]
[1,3,4,5,6] Department of Pharmacy, Godavari Institute of Pharmacy, Kolpa, Latur, Maharashtra.
[2]Department of Pharmaceutical Chemistry, Godavari Institute of Pharmacy, Kolpa, Latur, Maharashtra.

***Abstract*—Quality by Design (QbD) has emerged as a transformative approach in pharmaceutical development, aimed at building quality into products from the very beginning rather than testing it at the end. This systematic, science- and risk-based framework emphasizes a thorough understanding of processes, materials, and product performance to ensure consistent quality throughout a drug's lifecycle. Quality has been given an importance by all regulatory bodies for pharmaceutical products. Quality means customer satisfaction in terms of service, product, and process. The QbD paradigm integrates principles such as defining a Quality Target Product Profile (QTPP), identifying Critical Quality Attributes (CQAs), and establishing a robust Design Space through risk assessments and Design of Experiments (DoE). Regulatory bodies like the FDA and ICH have strongly endorsed QbD to enhance product efficacy, safety, and regulatory compliance. This review outlines the core elements of QbD, discusses its implementation strategies across different stages of drug development, and highlights the benefits and challenges associated with its adoption. Ultimately, QbD enables more efficient development, continuous improvement, and greater assurance of quality in pharmaceutical products. The analysis was per formed in view of an improved standardization between research teams, and should contribute to reduce the gap towards compliant Good Manufacturing Practice (cGMP) manufacturing.**

***Index Terms*—Quality By Design, Critical Quality Attributes, Pharmaceutical Analysis, Quality Target Product Profile**



Fig.1:- Graphical Presentation of Quality by design

I. INTRODUCTION

Quality by design (QbD) is a concept first developed by the quality pioneer Dr. Joseph M. Juran . This word contain to major word first one is quality and second is design. Regulatory bodies and pharmaceutical industries are constantly working to enhance the quality, safety, and efficacy of the products that are directly linked to patients' health.

Quality: - Quality is important word. So Quality is "standard or suitability for intended use." This term includes such attribute of the identity, potency and purity.

Quality by Design: It is a systemic approach that develops product design, process understanding, and process control based on quality risk management. Pharmaceutical industries aware of product Quality, Safety, and Efficacy. Regulatory authorities are always proposing the implementation of ICH quality guidelines such as Q8, Q9, Q10 & Q11. Application of QbD will provide knowledge and scientific understanding to support pharmaceutical development. Importance of Quality by Design (QbD) in the Pharmaceutical Industry

1. Enhanced Product and Process Understanding: - QbD requires a thorough understanding of the relationship between formulation components, process parameters, and product performance. This scientific understanding helps identify Critical Quality Attributes (CQAs), Critical Process Parameters (CPPs), and Critical Material Attributes (CMAs), allowing manufacturers to better predict and control variability.

2. Improved Product Quality and Consistency: - By designing processes within a defined Design Space, QbD ensures consistent product quality across different manufacturing batches. This reduces the likelihood of batch failures and minimizes the risk of recalls or regulatory non-compliance.

3. Risk-Based Decision Making: -QbD incorporates tools like risk assessment (e.g., Failure Mode and Effects Analysis, Fishbone Diagrams), which help prioritize critical variables and focus development efforts on areas of greatest impact on product quality.

4. Regulatory Flexibility and Compliance:- Regulatory agencies such as the U.S. FDA, EMA, and ICH (especially through guidelines Q8–Q11) strongly support QbD. Submissions incorporating QbD elements are often viewed favorably, and manufacturers may be granted more flexibility within the approved design space, facilitating post-approval changes without extensive regulatory re-evaluation.

5. Efficiency in Development and Manufacturing: - Implementation of QbD reduces time and cost in drug development by minimizing trial-and-error experimentation. It also improves technology transfer, scale-up, and commercialization due to well-characterized processes and control strategies.

6. Supports Lifecycle Management: - Through its focus on product and process knowledge, QbD provides a strong foundation for managing changes throughout the product lifecycle, including post-approval modifications and ongoing process optimization.



Fig No. 2: Building blocks of Quality by Design (Qbd); Key terms: QRM: Quality Risk Management; DoE: Design of Experiments; PAT: Process Analytical Technology

Advantages Of Qbd

1. QbD helps in providing safer, quality, and more efficient drug products.
2. QbD helps in safer and faster drug development.
3. It provides a higher level of assurance of drug product quality.
4. It increases efficiency of pharmaceutical manufacturing processes and reduces manufacturing costs and product rejects.
5. It provides more efficiency for regulatory oversight:

II. ELEMENTS OF QBD PROGRAM

1. QTPP: - Quality Target Product Profile
2. CQA: - Critical Quality Atributes
3. CMAS: - Critical Material Attributes
4. DS: - Design Space
5. PP: - Process Parameter



Fig No.3: - Application of PAT tools

1. Quality target product profile:
According to the ICH guideline. It is the quality profile of drug product that ideally will be achieved to ensure the desired. The quality target product profile (QTPP) as it relates to quality, safety, and efficacy, considering. It is an element for setting the target for drug product development. As a result, sufficient purity and quality of these products will be required for their successful development. The Target Product Profile (TPP) can be used to design the clinical trials, safety and ADME studies, as well as to de sign the drug product.
2. Critical quality attribute:
It is the physical, chemical, biological and microbiological property of drug that should be within an appropriate limit rang or distribution to ensure its intended safety, efficacy, stability and Performance desired quality. The use of CQA can be reserved for cases where there is a need to refer collectively to the targets of a QbD approach.
3. Critical material attribute:
Physical, chemical, biological and microbiological property of raw material that need to be monitored or controlled to ensure desired drug product quality. a set of critical material attributes (CMAs) that are independent of each other provide specific goals with which to evaluate a manufacturing process.
4. Design space:
It is designed for single and multiple unit operation or also for whole system. Process and product design and development cannot be separated since formulation cannot become a product without a process. This should include all the factors that need to be considered for the design of the process, including facility, equipment, and material transfer and manufacturing variables. Once design space is approved, regulatory post approval change requirements will be simplified approval inside vs. outside design space inside space.
5. Critical process parameter:
Critical Process Parameters (CPPs) are defined as the process inputs that exert a direct and significant influence on Critical Quality Attributes (CQAs) when varied within their normal operating range. Identifying and controlling CPPs is fundamental to ensuring consistent product quality, as any deviation beyond the acceptable range can negatively impact safety, efficacy, or stability of the final product. Closely associated with CPPs is the concept of process robustness, which refers to the ability of a manufacturing process to consistently deliver acceptable product quality and performance while tolerating variability in input materials and operating conditions. A robust process can accommodate

inherent variability without compromising the predefined quality attributes, thereby reducing the likelihood of deviations, batch failures, or product recalls. To further assess reproducibility and consistency, process capability is studied as a statistical measure of the inherent variability of a process in relation to its specification limits. It quantitatively evaluates how well a process performs in meeting quality standards and maintaining control over CPPs. Among various process capability indices, the six sigma methodology is one of the most widely recognized approaches, providing a benchmark for minimizing variability and ensuring near-perfect quality outcomes.

Current Approach	QbD Approach
Quality is assured by testing and inspection.	Quality is built into product & process by design and based on scientific understanding.
It includes only data intensive submission which includes disjointed information without "big picture".	It includes Knowledge rich submission which shows product knowledge & process understanding.
Here, any specifications are based on batch history.	Here, any specifications based on product performance requirements.
Here there is "Frozen process," which always discourages changes.	Here there is Flexible process within design space which allows continuous improvement.
It focuses on reproducibility which often avoids or ignores variation.	It focuses on robustness which understands and control variation.

FIG NO. 4: - Differancance Between Current Approcha and Qbd Approach

Regulatory Support for Quality by Design (QbD):

ICH Guidelines (International Conference on Harmonisation) :

The ICH has been the major driving force behind Qbd integration into regulatory expectations through the development of harmonized guidelines. Key ICH guidelines include:



Fig No. 5 And 6: - Content of quality by drug

1. ICH Q8 (R2): Pharmaceutical development

ICH Q8 guideline as a systematic approach to development that begins with predefined objectives and emphasizes product and process understanding and process control, based on sound science and quality risk management. the principles in this guideline are important to consider during those stages as well. This guideline might also be appropriate for other types of products. To determine the applicability of this guideline to a particular type of product, applicants can consult with the appropriate regulatory authorities.

2.ICH Q9: Quality Risk Management

Provides principles and examples of tools for quality risk management (e.g., FMEA, Ishikawa diagrams) that support risk-based decision-making throughout the product lifecycle. These aspects include development, manufacturing, distribution, and the inspection and submission/review processes throughout the lifecycle of drug substances, drug (medicinal) products, biological and biotechnological products

3. ICH Q10: Pharmaceutical Quality System

Advocates for a lifecycle approach to quality, covering development through commercialization and continuous improvement. This guideline applies to the systems supporting the development and manufacture of pharmaceutical drug substances (i.e., API) and drug products, including biotechnology and biological products, throughout the product lifecycle.

4. ICH Q11: Development and Manufacture of Drug Substances

ICH Q11 provides further clarification on the principles and concepts described in ICH Guidelines on Pharmaceutical Development (Q8), Quality Risk Management (Q9) and Pharmaceutical Quality System (Q10) as they pertain to the development and manufacture of drug substance. The purpose of this guideline, the terms “traditional” and “enhanced” are used to differentiate two possible approaches. ICH q11 provides clearity on regulatory expectation for including Qbd element in drug substance section of submission.

Challenges And Limitations Of (Qbd): -

1. High Initial Cost and Resource Requirements

Applying QbD calls for heavy investment in time, skills, and capital. The need for large-scale experimentation, sophisticated analytical tools, and statistical techniques can raise the initial development cost, which can be especially heavy for small and medium-sized companies.

2. Complexity of Implementation

The implementation of QbD involves multidisciplinary knowledge in pharmaceutical sciences, engineering, statistics, and regulatory affairs. Design space establishment, selection of critical quality attributes (CQAs) and critical process parameters (CPPs), and incorporation of risk management tools may be challenging and time-consuming.

3. Data Management Challenges

QbD creates huge amounts of experimental and process data, where strong data management systems are needed. The integration of advanced data analytics, knowledge management systems, and ensuring data integrity are still major challenges, particularly in weakly digitally equipped organizations.

4. Limited Regulatory Clarity and Harmonization

Although regulatory bodies like FDA, EMA, and ICH support QbD, submission content expectations and the level of detail may differ by geographic region. This global non-harmonization situation occasionally causes uncertainty among drug companies when preparing dossiers and making regulatory submissions.

5. Resistance to Change

The transition to QbD requires cultural and organizational transitions from conventional empirical practices. Most companies encounter resistance from employees because of inadequate training, unfamiliarity with statistical methods (e.g., Design of Experiments, multivariate analysis), and viewing QbD as another burden rather than a long-term advantage.

6. Issues in Validation and Standardization

Model validation, simulation validation, and prediction of design space to regulators' satisfaction continues to be a challenge. Very little standardization exists in the methodologies employed to determine and warrant design space, resulting in inconsistency of regulatory acceptability.

7. Legacy Products Applicability

Applying QbD retrospectively to already approved (legacy) products is usually not practicable because of scarce historical information, cost constraints, and the possible requirement for regulatory re-approval. Therefore, QbD use is more prevalent in new product development than in established products.

III. FUTURE PROSPECTS OF QUALITY BY DESIGN (QBD) AND INTEGRATION OF DIGITAL TOOLS

As the pharmaceutical industry continues to evolve in response to technological advancements and regulatory modernization, the future of Quality by Design (Qbd) lies in its seamless integration with digitalization, automation, and data-driven technologies. The next generation of Qbd often referred to as Digital QbD (dQbd) is expected to transform pharmaceutical development and manufacturing into more predictive, adaptive, and efficient systems.

1. Digital Transformation of QbD

The conventional QbD is based on formal frameworks, empirical data, and statistical software such as Design of Experiments (DoE) and multivariate analysis. However, with the introduction of Industry

4.0, the QbD paradigm of Qbd is widening to involve sophisticated digital tools like:
Artificial Intelligence (AI) and Machine Learning (ML)
These technologies are being used to examine vast from developmental and manufacturing processes for discovering concealed patterns, forecasting key outcomes, and optimize control strategies.
Process Analytical Technology (PAT) 2.0
Advanced PAT instrument combined with real-time analytics, sensors, and intelligent controllers support dynamic monitoring and control of CQAs and CPPs, enabling real-time release testing (RTRT) and adaptive control.
Digital Twins
A digital twin is a virtual replica of a physical process or product. In QbD, digital copy can be used to mimic different situation and forecast the effect of changes in formulation or process parameters will affect product quality—allowing for virtual experimentation and rapid optimization.
Cloud-based QMS and Data Management
Modern Quality Management Systems (QMS) are becoming cloud-based and combined with development platforms, allowing for improved data traceability, collaboration, and compliance tracking.
Knowledge Management Systems (KMS)
Digital KMS can store, retrieve, and apply knowledge across different stages of development and sites, ensuring efficient technology transfer and lifecycle management.
2. Benefits of Digital QbD
Faster Development
AI-based models minimize the necessity of large numbers of experimental runs through simulation and prediction of results, allowing for significantly shorter R&D cycles.
Decision Making Based on Data
Real-time data integration enables constant learning and informed changes during development as well as commercial manufacturing.
Enhanced Regulatory Compliance
Digital technologies provide more effective documentation, traceability, and audit-readiness, which are compliant with regulatory requirements in ICH Q8–Q11 and FDA's Quality Metrics Program.
Improved Risk Mitigation
Predictive analytics is used to detect and manage risks prior to their effect on product quality or patient safety.
3. Challenges and Considerations
Though digital QbD presents promising potential, there are some issues that need addressing:
Data Integrity and Security
Strong systems must be in place to guarantee data accuracy, integrity, and compliance with regulatory requirements such as 21 CFR Part 11.
Trained Workforce
Digital QbD implementation needs pharmaceutical science-trained personnel and data science-trained personnel.
Standardization and Validation
Digital tools and AI models need to be validated and standardized to provide reproducibility and reliability in regulatory
filings.
4. Future Outlook
Pharmaceutical development is on the cusp of embracing digital QbD tools as the new standard. Regulatory bodies are increasingly adopting data-driven submissions, and programs like the FDA's Emerging Technology Program (ETP) and EMA's digital innovation hubs facilitate such shifts. Over the next few years, we can anticipate:
Greater use of continuous manufacturing with digital controls in real-time
Stronger regulatory frameworks to support digital models and virtual trials
Increased adoption of predictive modeling, automation, and cloud-based platforms to handle quality throughout the product life cycle

IV. CONCLUSION

Quality by Design (Qbd) is a change in paradigm in pharmaceutical development, with the emphasis placed on designing quality into products right from the initial stages instead of depending on end-product testing. Through the incorporation of scientific understanding, risk management, and regulatory requirements, Qbd provides ensured consistency in product quality, safety, and efficacy in addition to encouraging process robustness and lifecycle management. While issues like high cost of implementation, complexity of data management, and harmonization of regulations persist, the long-term advantages such as decreased variability, enhanced regulatory flexibility, and economical manufacturing justify Qbd as a worthwhile framework for the pharm industry.

As advanced digital technologies are integrated into Quds, the future of Quds is transforming into Digital Quds (dQbD) which allows for predictive, adaptive, and data-driven decision-making. This evolution is in the direction of Industry 4.0 and will enhance continuous manufacturing, real-time quality control, and global regulatory compliance. Ultimately, Quds is not a regulatory necessity but a strategic method that promotes innovation, efficiency, and patient safety and is thus the foundation of contemporary pharmaceutical development.

REFERENCE

[1] development. Int J of Pharm Pharma Sci. 2014; 6:29-35. US Food and Drug Administration. Guidance for industry: Q8 (R2) pharmaceutical development. US Department of Health and Human Service, FDA, Rockville, MD; 2009.

[2] Khan, A., Naquvi, K. J., Haider, M. F., & Khan, M. A. (2024). Quality by design-newer technique for pharmaceutical product development. *Intelligent Pharmacy*, *2*(1), 122-129.

[3] Manuscript_f4c534f413d37e80841caa8096b914 7e Quality by design to de ne critical process parameters for mesenchymal stem cell expansion Charlotte Maillota, Caroline Siona, Natalia De Islab, Dominique Toyec, Eric Olmosa aLaboratoire Reactions et Genie des Procedes, Universite de Lorraine, CNRS, Nancy, France bIngenierie Moleculaire et Physiopathologie Articulaire, Universite de Lorraine, CNRS UMR 7365, 54500

[4] Zhang, L., & Mao, S. (2017). Application of quality by design in the current drug development. *Asian journal of pharmaceutical sciences*, *12*(1), 1-8.

[5] Verch, T., Campa, C., Chery, C. C., Frenkel, R., Graul, T., Jaya, N., ... & Ranheim, T. (2022). Analytical quality by design, life cycle management, and method control. The AAPS journal, 24(1), 34

[6] Yu, L. X., Amidon, G., Khan, M. A., Hoag, S. W., Polli, J., Raju, G. K., & Woodcock, J. (2014). Understanding pharmaceutical quality by design. *The AAPS journal*, *16*(4), 771-783.

[7] Darkunde, S. L. (2018). A review on quality by design. *International journal of pharmaceutical chemistry and analysis*, *5*(1), 1-6.

[8] Bhavyasri, K., Vishnumurthy, K. M., Rambabu, D., & Sumakanth, M. (2019). ICH guidelines–"Q" series (quality guidelines)-A review. *GSC Biol. Pharm. Sci*, *6*(3), 89-106.

[9] Nadpara, N. P., Thumar, R. V., Kalola, V. N., & Patel, P. B. (2012). Quality by design (QBD): A complete review. *Int J Pharm Sci Rev Res*, *17*(2), 20-8.

[10] Fukuda, I. M., Pinto, C. F. F., Moreira, C. D. S., Saviano, A. M., & Lourenço, F. R. (2018). Design of experiments (DoE) applied to pharmaceutical and analytical quality by design (QbD). *Brazilian journal of pharmaceutical sciences*, *54*, e01006

[11] Bhutani, H., Kurmi, M., Singh, S., Beg, S., & Singh, B. (2004). Quality by design (QbD) in analytical sciences: an overview. *Quality Assurance*, *3*, 39-45.

[12] Eon-Duval, A., Broly, H., & Gleixner, R. (2012). Quality attributes of recombinant therapeutic proteins: an assessment of impact on safety and efficacy as part of a quality by design development approach. *Biotechnology progress*, *28*(3), 608-622.

[13] Kadam, V. R., Patil, M. P., Pawar, V. V., & Kshirsagar, S. (2017). A review on: Quality by design (QbD). *Asian Journal of Research in Pharmaceutical Sciences*, *7*(4), 197-204.

[14] Patil, A. S., & Pethe, A. M. (2013). Quality by Design (QbD): A new concept for development of quality pharmaceuticals. *Int J Pharm Qual Assur*, *4*(2), 13-9.

[15] Bubshait, A. A., Farooq, G., Osama Jannadi, M., & Assaf, S. A. (1999). Quality practices in design organizations. *Construction Management & Economics*, *17*(6), 799-809.

[16] Lionberger, R. A., Lee, S. L., Lee, L., Raw, A., & Yu, L. X. (2008). Quality by design: concepts for ANDAs. *The AAPS journal*, *10*(2), 268-276.

[17] Verch, T., Campa, C., Chery, C. C., Frenkel, R., Graul, T., Jaya, N., ... & Ranheim, T. (2022). Analytical quality by design, life cycle management, and method control. *The AAPS journal*, *24*(1), 34.

[18] ICH Quality Implementation working group. Point to consider, ICH endorsed guide for ICH Q8/Q9/Q10 implementation. 2011
[19] Rath, T., Strong, D.O., Rath & Strong's Six Sigma Pocket Guide. Lexington, AON Consulting Worldwide, MA 2002
[20] US Food and Drug Administration. Guidance for industry: Q8 Pharmaceutical Development, US Department of Health and Human Service, FDA, Rockville, MD, May 2006.